Literature DB >> 17890217

Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.

A A M van der Veldt, A J M van den Eertwegh, K Hoekman, F Barkhof, E Boven.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17890217     DOI： 10.1093/annonc/mdm455

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  13 in total

Review 1.  Cognitive Effects of Chemotherapy and Cancer-Related Treatments in Older Adults.

Authors:  Jennifer N Vega; Julie Dumas; Paul A Newhouse
Journal:  Am J Geriatr Psychiatry       Date:  2017-04-06       Impact factor: 4.105

Review 2.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

Review 3.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

Review 4.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors:  Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal:  Target Oncol       Date:  2011-11-17       Impact factor: 4.493

5.  Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.

Authors:  Jessica E Pritchard; Lauren E Wilson; Samuel M Miller; Melissa A Greiner; Harvey Jay Cohen; Deborah R Kaye; Tian Zhang; Michaela A Dinan
Journal:  J Am Geriatr Soc       Date:  2022-05-02       Impact factor: 7.538

6.  Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.

Authors:  Adeline Yl Lim; Ignacio Segarra; Srikumar Chakravarthi; Sufyan Akram; John P Judson
Journal:  BMC Pharmacol       Date:  2010-10-15

Review 7.  Neurological adverse effects caused by cytotoxic and targeted therapies.

Authors:  David Schiff; Patrick Y Wen; Martin J van den Bent
Journal:  Nat Rev Clin Oncol       Date:  2009-08-25       Impact factor: 66.675

8.  Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

Authors:  Rebecca A Miksad; Kuan-Chi Lai; Marion C Stein; Megan E Healy; Rafael Rojas; Katherine M Krajewski; Andrew X Zhu
Journal:  J Gastrointest Cancer       Date:  2009

9.  Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

Authors:  A A M van der Veldt; E Boven; H H Helgason; M van Wouwe; J Berkhof; G de Gast; H Mallo; C N Tillier; A J M van den Eertwegh; J B A G Haanen
Journal:  Br J Cancer       Date:  2008-07-01       Impact factor: 7.640

10.  Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.

Authors:  Sasja F Mulder; Dirk Bertens; Ingrid M E Desar; Kris C P Vissers; Peter F A Mulders; Cornelis J A Punt; Dick-Johan van Spronsen; Johan F Langenhuijsen; Roy P C Kessels; Carla M L van Herpen
Journal:  BMC Cancer       Date:  2014-03-24       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.